The ascendancy of Viagra and its influence on the pharmaceutical landscape presents a complex question for shareholders. While the first sales statistics were astounding, the exclusivity has ended, leading to a deluge of off-brand alternatives that are eroding revenue. Moreover, the sector is facing issues related to population trends and changi… Read More